Navigation Links
Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
Date:5/18/2009

BRUSSELS, May 18 /PRNewswire/ -- Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global codevelopment of novel biopharmaceutical product opportunities originating in China.

Through this agreement, Solvay Pharmaceuticals will gain access to HUYA's comprehensive Chinese molecule portfolio, focusing specifically on compounds in the cardiovascular area. As some of these molecules are already in advanced stages of development in China, the partnership will help Solvay Pharmaceuticals speed up its early discovery activities as well as increase the company's chances for successfully developing innovative new therapies as safety or efficacy information is already available for some of these molecules.

The pace and quality of China's innovation in the life sciences have led to a significant increase in new product opportunities. Through key collaborations with China's leading academic and commercial organizations, HUYA has gained access to these opportunities to enable and accelerate their worldwide development and commercialization. HUYA has thereby built a most comprehensive Chinese compound portfolio, including a significant number of product candidates targeting cardiovascular diseases to which Solvay Pharmaceuticals will have access under this strategic partnership.

"We look forward to working with HUYA and its highly qualified Chinese partners to identify innovative new molecules and develop them into break-through new therapies for patients and physicians around the globe," said Werner Cautreels, PhD, CEO of Solvay Pharmaceuticals. "We believe that through this partnership, we will be able to speed up our R&D activities by gaining access to compounds that could be introduced in more advanced stages of early development."

According to Mireille Gingras, PhD, President and CEO of HUYA, "This partnership with Solvay Pharmaceuticals further validates HUYA's model for co-developing in Western markets novel therapeutic compounds sourced from China. Moreover, it leverages our demonstrated capabilities and experience in cardiovascular drug development. We are pleased to partner with Solvay Pharmaceuticals on new opportunities for development."

About Solvay Pharmaceuticals

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. The companies seek to fulfil carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2008 sales were EUR 2.7 billion and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.

About HUYA Bioscience International

HUYA Bioscience International is a leader in enabling and accelerating the global codevelopment of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical academic and commercial organizations to speed development and value creation in world-wide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA is jointly headquartered in San Diego, CA, and Shanghai, PRC. Additional information about the company is available at www.huyabio.com.

    For more information, please contact:

    Media contacts HUYA Bioscience International:
    Juliet Travis
    (510) 452-3771
    juliet@travispr.com

    Solvay Pharmaceuticals:
    Sven Voet
    Global Communications
    Phone: + 32 2 509 68 11
    sven.voet@solvay.com

    HUYA Bioscience International:
    USA:                               China:
    Jan Tuttleman, PhD                 Li Zhu, PhD
    Vice President, Marketing          VP China Operations
    HUYA Bioscience International,     LLC HUYA Bioscience International, LLC
    (858) 798-8800                     86 (21) 51323312
    jtuttleman@huyabio.com             lzhu@huyabio.com


'/>"/>
SOURCE Solvay Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
2. 40 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM)
3. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 MiMedx Group, Inc. (NASDAQ: MDXG), ... placental tissue allografts and patent-protected processes to develop and ... healthcare, announced today  that it will present at the ... , NY.  Parker H. "Pete" Petit, Chairman and CEO, ... Christopher M. Cashman , EVP and Chief Commercialization Officer, ...
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" ... in China , today announced that its board ... expiration date of the plan from March 27, 2017 to March ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
Breaking Biology Technology:
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/1/2017)...  Aware, Inc. (NASDAQ: AWRE), a leading supplier of ... Moberg has resigned, effective March 3, 2017, as ... and Treasurer of Aware citing a desire to retire.  ... of the Board of Directors of Aware. ... and co-President, General Counsel has been named Chief Executive ...
Breaking Biology News(10 mins):